DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/kn8svz/u_s_orthopedic) has announced the addition of the "U.S. Orthopedic Biomaterials Market - 2015 (Executive Summary)" report to their offering.
The fastest growing segments involve stem cells, namely the segments for stem cell bone grafts and concentrated bone marrow. The products within these markets offer the greatest regenerative potential for healing bone.
Orthopedic biomaterial products compete with products that are more established and less expensive. Thus, clinical evidence is often an important deciding factor for orthopedic biomaterials over conventional forms of therapy especially in regards to reimbursement. However, the promise seen in some products such as bone marrow concentrate generates growth despite a lack of clinical evidence and reimbursement.
Key Topics Covered:
- U.S. Market For Orthopedic Biomaterials
- Orthopedic Bone Graft Substitute Market
- Orthopedic Growth Factor Market
- Orthopedic Stem Cell Market
- Orthopedic Cell Therapy Market
- Orthopedic Hyaluronic Acid Viscosupplementation Market
- Orthopedic Cartilage Repair Market
- Spinal Machined Bone Allograft Market
- Leading Competitors
- Aastrom
- Allosource
- Anika Therapeutics
- Artrhex
- Baxter
- Biomet
- Bioventus
- DePuy Synthes
- Exactech
- Ferring Pharmaceuticals
- Fidia Pharmaceuticals
- Genzyme
- Harvest
- Integra LifeSciences
- MTF
- Medtronic
- NuVasive
- Orthofix
- RTI Surgical
- Stryker
- Wright Medical
- Zimmer
For more information visit http://www.researchandmarkets.com/research/kn8svz/u_s_orthopedic
